NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/07/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization5,246.31 mln
Float83.09 mln
Earnings Date07/30/2026
EPS
0.18
Overpriced
P / E
228
Bubble territory
Piotroski F-Score
7
/ 9
Strong
Beneish M-Score
-2.45
Borderline
1-Year Forecast
40.93
Fairly priced
Relative Strength
43
/ 100
Slightly lagging
Business Description
Apellis Pharmaceuticals is a US-based drug company that develops and sells treatments for serious diseases that currently have few or no good options for patients. Its two approved medicines address a rare blood disorder and a leading cause of vision loss in older adults, while several additional treatments are in various stages of development. The company also works with partners, including Swedish Orphan Biovitrum and Beam Therapeutics, to expand its research into genetic and complement-related diseases. Founded in 2009 and based in Waltham, Massachusetts, Apellis continues to build on its internal capabilities to bring new therapies to patients.
